PharmGKB summary: Efavirenz pathway, pharmacokinetics.
作者信息
McDonagh Ellen M, Lau Johnathan L, Alvarellos Maria L, Altman Russ B, Klein Teri E
机构信息
Departments of aGenetics bBioengineering, School of Medicine, Stanford University, Stanford, California, USA cDepartment of Immunology, University of Toronto, Toronto, Ontario, Canada.
出版信息
Pharmacogenet Genomics. 2015 Jul;25(7):363-76. doi: 10.1097/FPC.0000000000000145.
Abstract
摘要
相似文献
1
PharmGKB summary: Efavirenz pathway, pharmacokinetics.药物基因组学知识库总结：依非韦伦途径，药代动力学。
Pharmacogenet Genomics. 2015 Jul;25(7):363-76. doi: 10.1097/FPC.0000000000000145.
2
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.依法韦仑已知和新型Ⅰ期及Ⅱ期代谢产物在血浆、尿液和脑脊液中的体内分析及分布
Drug Metab Dispos. 2016 Jan;44(1):151-61. doi: 10.1124/dmd.115.065839. Epub 2015 Nov 9.
3
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.初治HIV感染患者每日一次依非韦伦（400毫克与600毫克）的药代动力学和药效学比较：ENCORE1研究结果
Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14.
4
Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations.CYP2B6、CYP2A6、UGT2B7 和 CAR 多态性对依非韦伦血药浓度影响的荟萃分析。
J Antimicrob Chemother. 2019 Nov 1;74(11):3281-3290. doi: 10.1093/jac/dkz329.
5
Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.海地太子港功能性CYP2B6变体与含依非韦伦方案的病毒学反应
J Antimicrob Chemother. 2014 Aug;69(8):2187-90. doi: 10.1093/jac/dku088. Epub 2014 Apr 2.
6
Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.非洲人群 HIV 治疗中 CYP2B6、CYP2A6 和 UGT2B7 的药物遗传学：以依非韦伦和奈韦拉平为例。
Drug Metab Rev. 2015 May;47(2):111-23. doi: 10.3109/03602532.2014.982864. Epub 2014 Nov 13.
7
Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.CYP2B6和CYP2A6基因变异解释了不同种族来源的HIV感染儿童中依非韦伦血浆浓度的个体间差异。
PLoS One. 2017 Sep 8;12(9):e0181316. doi: 10.1371/journal.pone.0181316. eCollection 2017.
8
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.CYP2B6、ABCB1 和 CYP3A5 多态性对依非韦伦药代动力学和治疗反应的影响：一项艾滋病临床治疗试验组研究。
J Infect Dis. 2010 Sep 1;202(5):717-22. doi: 10.1086/655470.
9
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.宿主遗传因素对 HIV-1 感染患者中依非韦伦的血浆和细胞内药代动力学的影响。
Pharmacogenomics. 2010 Sep;11(9):1223-34. doi: 10.2217/pgs.10.94.
10
Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers.CYP2B6 活性评分对健康志愿者单次给予依非韦伦的药代动力学和安全性的影响。
Pharmacogenomics J. 2020 Apr;20(2):235-245. doi: 10.1038/s41397-019-0103-3. Epub 2019 Oct 18.
引用本文的文献
1
CYP2B6 genetic variation in cyclophosphamide metabolism and hemorrhagic cystitis in Fanconi anemia patients undergoing allogeneic hematopoietic cell transplantation: A descriptive genetic association study.接受异基因造血细胞移植的范可尼贫血患者中，CYP2B6基因变异与环磷酰胺代谢及出血性膀胱炎的关系：一项描述性基因关联研究。
Medicine (Baltimore). 2025 Mar 21;104(12):e41937. doi: 10.1097/MD.0000000000041937.
2
Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease Therapeutics.考虑将依非韦伦用于阿尔茨海默病治疗的药物重新利用的挑战与机遇
ACS Pharmacol Transl Sci. 2024 Sep 6;7(10):2924-2935. doi: 10.1021/acsptsci.4c00229. eCollection 2024 Oct 11.
3
Factors Associated With Long-term Retention in Antiretroviral Therapy Among People Living With HIV: Evidence From a Tertiary Hospital in Jakarta, Indonesia.与印度尼西亚雅加达一家三级医院的 HIV 感染者长期保留抗逆转录病毒治疗相关的因素。
J Prev Med Public Health. 2024 May;57(3):252-259. doi: 10.3961/jpmph.23.512. Epub 2024 Apr 30.
4
Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study.基于突变效应分析、分子动力学、分子对接和药效团模型研究的 HIV 逆转录酶抑制剂的药效团模型的建立。
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241231465. doi: 10.1177/03946320241231465.
5
Efavirenz: History, Development and Future.依非韦伦：历史、研发与未来。
Biomolecules. 2022 Dec 31;13(1):88. doi: 10.3390/biom13010088.
6
Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz.CYP2B6 等位基因在主要伊朗族群中的频率，影响依非韦伦的反应。
Genet Res (Camb). 2022 Oct 19;2022:5754776. doi: 10.1155/2022/5754776. eCollection 2022.
7
and Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study.基因型预测长期接受基于依非韦伦的抗逆转录病毒治疗的HIV患者的葡萄糖代谢紊乱：一项病例对照研究。
J Pers Med. 2022 Jun 30;12(7):1087. doi: 10.3390/jpm12071087.
8
Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.用于改善新冠病毒疾病治疗的药物遗传学和精准医学方法。
Front Pharmacol. 2022 Feb 18;13:835136. doi: 10.3389/fphar.2022.835136. eCollection 2022.
9
Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study.埃塞俄比亚HIV感染儿童中依非韦伦血浆暴露量、自身诱导情况及药物遗传学变异影响的预测因素：一项前瞻性队列研究
J Pers Med. 2021 Dec 5;11(12):1303. doi: 10.3390/jpm11121303.
10
Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele.巴布亚新几内亚艾滋病毒/艾滋病患者的血浆依非韦伦浓度存在较大差异，与 CYP2B6 516T 等位基因的高频率相关。
Clin Transl Sci. 2021 Nov;14(6):2521-2531. doi: 10.1111/cts.13120. Epub 2021 Aug 20.
本文引用的文献
1
Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics.依法韦仑剂量减少：一项描述成本效益、药代动力学和药物遗传学的观察性研究。
Pharmacogenomics. 2014 May;15(7):997-1006. doi: 10.2217/pgs.14.48.
2
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.HIV感染的携带CYP2B6慢代谢基因型的成年患者的次生代谢途径多态性与血浆依法韦仑浓度
J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11.
3
Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.海地太子港功能性CYP2B6变体与含依非韦伦方案的病毒学反应
J Antimicrob Chemother. 2014 Aug;69(8):2187-90. doi: 10.1093/jac/dku088. Epub 2014 Apr 2.
4
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.接受含依非韦伦抗逆转录病毒治疗且接受或未接受基于利福平抗结核治疗的华裔HIV感染者的治疗药物监测和药物遗传学研究
PLoS One. 2014 Feb 14;9(2):e88497. doi: 10.1371/journal.pone.0088497. eCollection 2014.
5
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.泰国HIV-1感染成年患者中血浆依非韦伦浓度低于治疗水平的药物遗传学及临床生物标志物
Drug Metab Pharmacokinet. 2014;29(4):289-95. doi: 10.2133/dmpk.dmpk-13-rg-077. Epub 2014 Jan 28.
6
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.CYP 多态性、代谢中的种族和性别差异对剂量策略的影响：以依非韦伦为例。
Eur J Clin Pharmacol. 2014 Apr;70(4):379-89. doi: 10.1007/s00228-013-1634-1. Epub 2014 Jan 5.
7
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.遗传多态性在细胞色素 P450 中的作用以及结核分枝杆菌共治疗对 CYP2B6 SNPs 预测值的影响及其对成年 HIV 患者依非韦伦血药浓度的影响。
Antiviral Res. 2014 Feb;102:44-53. doi: 10.1016/j.antiviral.2013.11.011. Epub 2013 Dec 5.
8
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.在加纳 HIV 感染患者的回顾性队列中，药物遗传学与血浆依非韦伦浓度和临床相关因素的关联。
J Antimicrob Chemother. 2014 Feb;69(2):491-9. doi: 10.1093/jac/dkt372. Epub 2013 Sep 29.
9
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.基于依非韦伦和利福平异烟肼的抗结核治疗药物药物相互作用对 CYP2B6 和 NAT2 遗传多态性的依赖性：柬埔寨 ANRS 12154 研究。
J Infect Dis. 2014 Feb 1;209(3):399-408. doi: 10.1093/infdis/jit466. Epub 2013 Aug 29.
10
Impact of pharmacogenetics on CNS side effects related to efavirenz.基于药物遗传学的 efavirenz 相关中枢神经系统副作用的影响。
Pharmacogenomics. 2013 Jul;14(10):1167-78. doi: 10.2217/pgs.13.111.
Zotero 插件